Tocagen (TOCA) Earning Somewhat Favorable News Coverage, Analysis Finds

News articles about Tocagen (NASDAQ:TOCA) have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tocagen earned a news impact score of 0.14 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.5305208560233 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Separately, Zacks Investment Research cut shares of Tocagen from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th.

Tocagen (NASDAQ TOCA) opened at $10.86 on Friday. Tocagen has a 1 year low of $8.60 and a 1 year high of $17.95. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.03 and a quick ratio of 6.03.

Tocagen (NASDAQ:TOCA) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.02). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. analysts forecast that Tocagen will post -2.88 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by Week Herald and is the property of of Week Herald. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at

About Tocagen

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Insider Buying and Selling by Quarter for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with's FREE daily email newsletter.

Leave a Reply